NFL Biosciences Raises Efficacy Targets for Smoking Cessation Drug Candidates with Novel Mechanism Discovery

NFL Biosciences (搜索)搜索该词条 has announced a significant advancement in its smoking cessation (搜索)搜索该疾病 drug development program, revealing novel mechanisms of action for its botanical drug candidates that target the underlying neural changes caused by tobacco addiction (搜索)搜索该疾病. The French biopharmaceutical company is now pursuing a dual-candidate strategy with raised efficacy targets based on new mechanistic insights.

Novel Mechanism Discovery Targets Persistent Neural Changes

The company has identified that smoking induces lasting immune changes, and subcutaneous administration of tobacco extracts reactivates pre-existing immune memory in smokers, inducing a transient innate immune signal associated with normalization of brain biomarkers affected by smoking cessation (搜索)搜索该疾病.

Preclinical studies conducted by the French Alternative Energies and Atomic Energy Commission (搜索)搜索该词条 (CEA) revealed distinct mechanisms for the two drug candidates. NFL-101查看药品详情 acts primarily on neuroinflammation (搜索)搜索该疾病, reducing expression of several markers including cytokines and growth factors involved in smoking-related inflammation (p < 0.001 to p < 0.0001).

NFL-102 (搜索)搜索该药品 demonstrates a more comprehensive approach, significantly normalizing signaling pathways that remain overactive during smoking cessation (搜索)搜索该疾病. The compound significantly lowers CREB (搜索)搜索该靶点 (p < 0.001), NF-κB (搜索)搜索该靶点 (p < 0.05), and JNK (搜索)搜索该靶点 (p < 0.001), while also reducing smoking-associated astrogliosis with a significant decrease in GFAP (搜索)搜索该靶点 (p < 0.01) and decreasing expression of pro-inflammatory cytokines (p < 0.01 to p < 0.0001).

Targeting CREB Pathway Offers Differentiated Approach

Nicolas Tournier, Pharmacologist and Director of the Pharmacological Neuroimaging Team at the CEA, explained the significance of these findings: "Smoking cessation (搜索)搜索该疾病 often fails because the brain remains permanently marked by tobacco. Our results suggest that there is a persistent neuroimmune context and lasting changes in neural signaling, particularly in the prefrontal cortex, which could contribute to weakened impulse control and increase the risk of relapse."

The CREB (搜索)搜索该靶点 signaling pathway represents a critical target, as current scientific research identifies it as a major regulator of tobacco addiction (搜索)搜索该疾病 involved in maladaptive neuroplasticity and reorganization of neural circuits underlying addictive behaviors. Unlike current smoking cessation (搜索)搜索该疾病 treatments that primarily act on nicotinic receptors (搜索)搜索该靶点 to alleviate withdrawal symptoms, NFL-102 (搜索)搜索该药品 acts downstream of these receptors, modulating signaling pathways permanently altered by smoking.

Dual-Candidate Strategy Targets Different Populations

Based on additional analyses of CESTO2 study participants, NFL Biosciences (搜索)搜索该词条 has identified that participants with certain characteristics demonstrate significantly higher sustained abstinence rates. Preliminary results from approximately 60 participants suggest efficacy between 35% and 60% in a subpopulation representing approximately one-third of the general population, compared to the 24.1% continuous abstinence rate observed in the general population.

Bruno Lafont, CEO and Co-founder of NFL Biosciences (搜索)搜索该词条, stated: "This in-depth understanding of the mechanism of action of tobacco extracts as smoking cessation (搜索)搜索该疾病 treatments now enables the company to deploy a more ambitious strategy, targeting higher levels of efficacy, secured by NFL-101查看药品详情, which only needs to confirm its efficacy in a subpopulation specifically selected for its better response, while NFL-102 (搜索)搜索该药品 is based on a composition with an extended mechanism of action designed to enhance efficacy across the entire smoking population."

Streamlined Clinical Development Strategy

The company has revised its clinical development approach based on these mechanistic insights. For NFL-101查看药品详情, the initial two-part Phase 3 design is no longer necessary, with development proceeding directly to a pivotal Phase 3 study in the identified high-response subpopulation, significantly reducing the number of participants and development costs compared to the original general population plan.

For NFL-102 (搜索)搜索该药品, the company plans to file a Phase 2b clinical trial application in mid-2026. This dose selection study will be conducted in France at approximately ten clinical centers, including 450 participants in a double-blind, placebo-controlled trial. Four doses will be evaluated, with the primary endpoint being continuous abstinence for 4 weeks, measured between day 15 and day 43 and confirmed by urinary cotinine testing.

Extended Intellectual Property Protection

NFL Biosciences (搜索)搜索该词条 has filed a new patent application in January 2026 for the NFL-102 (搜索)搜索该药品 composition, extending intellectual property protection until 2047 and broadening scope to other addictions beyond tobacco and nicotine, including alcohol, psychostimulants, opioids, and cannabinoids. This extension is based on the central role of the CREB (搜索)搜索该靶点 signaling pathway in neurobiological mechanisms common to these addictions.

The company has also obtained complementary characterization results for NFL-101查看药品详情 in accordance with guidance from European regulatory agencies and the U.S. FDA, providing precise description of constituent families and ensuring lot-to-lot reproducibility control.